Downstream Processing of Biopharmaceuticals

Downstream processing encompasses the sequence of operations required to isolate, purify and formulate a biopharmaceutical product from crude biological feedstock. Following cell culture or fermentation, unit operations such as cell removal, chromatographic separations, filtration and viral clearance are employed to achieve the high purity, yield and safety demanded by regulators. Advances in membrane technologies, affinity ligands and continuous‐flow systems have transformed the field, enabling more efficient capture of target molecules and removal of impurities such as host cell proteins and DNA. The integration of process analytical technologies and quality by design principles ensures consistent product quality, while single‐use and modular platforms offer flexibility and reduced capital expenditure. As biologics diversify beyond monoclonal antibodies to include recombinant enzymes, vaccines and gene therapies, downstream platforms must accommodate varying molecular sizes, stabilities and regulatory requirements. Environmental and economic pressures have driven efforts to miniaturise footprint, lower water and solvent usage, and transition towards continuous or hybrid batch–continuous manufacturing to meet global demand for affordable, high‐quality medicines.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Downstream Processing of Biopharmaceuticals publication trend

The graph below shows the total number of articles in downstream processing of biopharmaceuticals across all publications each year (not limited to Nature Index journals).

Technical terms

Downstream processing: The series of purification and formulation steps applied after bioproduction to isolate a target molecule at regulatory-compliant purity and potency.

Chromatography: A separation technique in which components of a mixture are separated based on differential interactions with a stationary phase and a mobile phase, commonly used for capture and polishing steps.

Single-use technology: Disposable bioprocess equipment designed for one-time use, reducing cleaning requirements, cross-contamination risk and capital investment.

Perfusion: A continuous cell culture strategy in which fresh medium is supplied and spent medium removed at a controlled rate, often coupled directly to downstream capture to maintain high productivity.

Multi-column chromatography: A continuous separation approach using multiple small columns operating in staggered cycles to enhance resin utilisation and throughput relative to batch operation.

References

1. Continuous downstream processing. Separation and Purification Technology (2024).
2. Transfer of a three step mAb chromatography process from batch to continuous: Optimizing productivity to minimize consumable requirements. Journal of Biotechnology (2016).
3. Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable Without a Digital-Twin?. Processes (2019).
4. A Single-use Strategy to Enable Manufacturing of Affordable Biologics. Computational and Structural Biotechnology Journal (2016).
5. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnology Progress (2017).